Renal Denervation: a Field in Flux

Current Hypertension Reports

Volumn 18, Issue 7, 2016, Pages

  Laffin, Luke J ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Hypertension; Renal denervation; Treatment resistant hypertension

Indexed keywords

ABLATION CATHETER; ETHNIC DIFFERENCE; HUMAN; KIDNEY DENERVATION; MEDICATION COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; TREATMENT FAILURE; VALIDATION STUDY; DENERVATION; DRUG EFFECTS; HYPERKALEMIA; KIDNEY; PATHOPHYSIOLOGY; PROCEDURES; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

SODIUM; SODIUM ZIRCONATE; ZIRCONIUM;

DENERVATION; HUMANS; HYPERKALEMIA; HYPERTENSION, RENAL; KIDNEY; RENIN-ANGIOTENSIN SYSTEM; SODIUM; ZIRCONIUM;

EID: 84973855828     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-016-0666-1     Document Type: Review

References (25)

1. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. Only major sham-controlled trial of renal denervation. It did not demonstrate any difference between renal denervation and sham procedure with respect to office blood pressure.
2. Papademetriou V, Tsioufis C, Doumas M. Renal denervation and Symplicity HTN-3: “Dubium sapientiae initium” (doubt is the beginning of wisdom). Circ Res. 2014;115(2):211–4.
3. Esler M. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens. 2014;8(8):593–8.
4. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.
5. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.
6. Group SR, Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.
7. Taler SJ. Treatment of resistant hypertension. Curr Hypertens Rep. 2005;7(5):323–9.
8. Laffin LJ, Bakris GL. Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol. 2015;21:20–4.
9. Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64(11):1071–8.
10. Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D’Agostino R, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314–21. 12-month ambulatory and office blood pressure results from SYMPLICITY HTN-3. Data support no further reduction in office or ambulatory BP after 1-year of follow-up.
11. Lambert T, Nahler A, Reiter C, Schwarz S, Gammer V, Blessberger H, et al. Frequency of renal artery stenosis after renal denervation in patients with resistant arterial hypertension. Am J Cardiol. 2015;115(11):1545–8.
12. Schmid A, Schmieder R, Lell M, Janka R, Veelken R, Schmieder RE, et al. Mid-term vascular safety of renal denervation assessed by follow-up MR imaging. Cardiovasc Intervent Radiol. 2016;39(3):426–32.
13. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635–43.
14. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–27.
15. Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol. 2015;66(16):1766–75. Preclinical porcine model of renal denervation established following negative results of SYMPLICITY HTN-3 that characterizes the types of ablations needed to maximally decrease norepinephrine levels and renal vasculature axon density.
16. Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med. 2014;370(15):1454–7.
17. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68.
18. Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 Study. Hypertension. 2015;65(2):407–13.
19. Rosa J, Widimsky P, Waldauf P, Lambert L, Zelinka T, Taborsky M, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 Study. Hypertension. 2016;67(2):397–403.
20. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–65.
21. Sun D, Li C, Li M, Liu J, Wen S. Renal denervation vs pharmacotherapy for resistant hypertension: a meta-analysis. J Clin Hypertens (Greenwich). 2015. doi:10.1111/jch.12742. Meta-analysis of 9 renal denervation versus pharmacotherapy trials in resistant hypertension, of which 6 were randomized. When only accounting for 6 randomized trials there was no difference in blood pressure lowering with renal denervation versus pharmacotherapy.
22. Bohm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015;65(4):766–74. First published data from a prospective registry created to document the long-term safety and effectiveness of renal denervation in a real world patient population with hypertension. It also aims to gather data for other diseases characterized by elevated sympathetic drive.
23. Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66(1):126–33.
24. Hyman DJ, Pavlik V. Medication adherence and resistant hypertension. J Hum Hypertens. 2015;29(4):213–8.
25. Ricke J, Seidensticker M, Becker S, Schiefer J, Adamchic I, Lohfink K, et al. Renal sympathetic denervation by CT-guided ethanol injection: a phase II pilot trial of a novel technique. Cardiovasc Intervent Radiol. 2016;39(2):251–60.